RxDoctor Payments Data

Katerina Jones

Adult Health · Gastonia, NCNPI 1346513223

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,771 of the $16,098 with a category attached, or 79.3%. Apellis Pharmaceuticals, Inc. accounts for 66.0% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $8,712, more than ten times the $56 reported in 2021. Among adult health clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,098in general payments, 2019–2025

Across 42 payments — averaging $383.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$11K
  • Novartis$5K
  • Vifor Pharma, Inc.$160
  • AstraZeneca$124
  • GSK$121
  • Akebia Therapeutics Inc$85
  • plus $171 from 5 others

What the payments were for

  • Consulting fees$12,77179%
  • Travel & lodging$1,96012%
  • Food & beverage$1,3688%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,098 in reported general payments places this provider in the 95th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,575
Medicare patients
191
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate21$60,085
VelphoroSucroferric Oxyhydroxide19$48,703
Sevelamer Carbonate158$25,113
VeltassaPatiromer Calcium Sorbitex26$23,880
Lanthanum Carbonate16$19,314
Calcium Acetate21$2,597
Torsemide40$933
Calcitriol91$848
Lidocaine-PrilocaineLidocaine/Prilocaine28$748
Omeprazole23$458
Metoprolol Succinate14$416
Midodrine Hcl16$390
Famotidine27$350
Potassium Chloride15$281
Ondansetron Hcl12$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$85$60,08521 claims
Fresenius USA Marketing, Inc.Velphoro$42$48,70319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 adult health providers in North Carolina.

Other adult health in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →